Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone

Journal of Substance Abuse Treatment

Volumn 24, Issue 3, 2003, Pages 251-255

  Ahmadi, Jamshid ^a,b   Ashkani, Hamid ^a   Ahmadi, Mojtaba ^a   Ahmadi, Nahid ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cigarette smoking; Clonidine; Naltrexone; Nicotine gum; Relapse prevention

Indexed keywords

CLONIDINE; NALTREXONE; NICOTINE GUM;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; TASTE DISORDER; THROAT DISEASE; TOBACCO DEPENDENCE;

EID: 0142029508     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(03)00027-8     Document Type: Article

References (25)

1. Ahmadi J., Khalili H., Jooybar R., Namazi N., Mohammadaghaei P. Prevalence of cigarette smoking in Iran. Psychological Reports. 89:2001;339-341.
2. Diagnostic and statistical manual of mental disorders. 4th ed:1994;American Psychiatric Association, Washington, DC.
3. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Experimental and Clinical Psycharmacology. 2:1994;244-268.
4. Blondal T., Gudmundsson L.J., Tomasson K., Jonsdottir D., Hilmarsdottir H., Kristjansson F., Nilsson F., Bjornsdottir U.S. The effects of fluoxetine combined with nicotine inhalers in smoking cessation. A randomized trial. Addiction. 94:1999;1007-1015.
5. Bobo J.K., Gilchrist L.D. Urging the alcoholic client to quite smoking cigarettes. Addictive Behavior. 8:1983;292-305.
6. Breslau N., Kilbey M.M., Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry. 48:1991;1069-1074.
7. Fiore M.C., Smith S.S., Jorenby D.E., Baker T.B. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. Journal of the American Medical Association. 271:1994;1940-1947.
8. Fiore M.C., Bailey W.C., Cohen S.J., Dorfman S.F., Goldstein M.G., Gritz E.R., Heyman R.B., Jaen C.R., Kottke T.E., Lando H.A., Mecklenburg R.E., Mullen P.D., Nett L.M., Robinson L., Stizer M.L., Tommasello A.C., Villejo L., Wewers M.E. Treating Tobacco Use and Dependence: Clinical practice guideline. 2000;US Department of Health and Human Services, Public Health Service, Rockville, MO.
9. Garvey A.J., Bliss R.E., Hitchcock J.W., Rosner B. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addictive Behaviors. 17:1992;367-377.
10. Gorelick D.A., Rose J., Jarvik M.E. Effect of naloxone on cigarette smoking. Journal of Substance Abuse. 1:1989;153-159.
11. Hurt R.D., Eberman K.M., Slade J. Treating nicotine addiction in patients with other addictive disorders. Orleans C.T., Slade J. Nicotine addiction: Principles and management. 1993;310-326 Oxford University Press, New York.
12. Hurt R.D., Lauger G.G., Offord K.P., Kottke T.E., Dale L.C. Nicotine-replacement therapy with use of a transdermal nicotine patch-a randomized double-blind placebo-controlled trial. Mayo Clinic Proceedings. 65:1990;1529-1537.
13. Karras A., Kane J.M. Naloxone reduces cigarette smoking. Life Sciences. 27:1980;1541-1545.
14. Nemeth-Coslett R., Griffiths R.R. Naloxone dose not affect cigarette smoking. Psychopharmacology. 89:1986;261-264.
15. O'Malley S.S., Croop R.S., Wroblewski J.W., Labriola D.F., Volpicelli J.R. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Annals. 25:1995;681-688.
16. Palmer R.F., Berens A. Double-blind study of the effect of naltrexone on the pleasure of smoking. Federation Proceedings. 42:1983;654.
17. Pomerleau O.F., Fertig J.B., Seyler L.E., Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology. 82:1983;530-537.
18. Sutherland G., Stapleton J.A., Russell M.A.H., Feyerabend C. Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology. 120:1995;418-425.
19. Shiffman S., Gitchell J.G. Increasing quitting by increasing access to treatment medications: USA. Tobacco Control. 8:2000;230.
20. Shiffman S., Gitchell J.G., Pinney J.M., Burton S.L., Kemper K.E., Lara E.A. Public health impact of over-the-counter nicotine medications. Tobacco Control. 6:1997;505-516.
21. Shiffman S., Rolf C.N., Hellebusch S.J., Gorsleine J., Gorodetzky C.W., Chiang Y., Schleusener D.S., Di Marino M.E. Real-word efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 97:2002;505-516.
22. Silagy C., Mant T., Flower G., Lancaster T. Nicotine replacement therapy for smoking cessation. The Cochrane Library, 1. 2000.
23. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry. 49:1992;876-880.
24. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., Hurt R.D. A randomized trial of naltrexone for smoking cessation. Addiction. 94:1999;1227-1237.
25. The ICD-10 classification of mental and behavioral disorder - diagnostic criteria for research. 1993;World Health Organization, Geneva.